Introduction
CD38Daratumumab, AL amyloidosis, amyloidosis, on-tumor
DISORDER, AL AMYLOIDOSIS, AMYLOIDOSIS
Immunoglobulin light-chain (AL) amyloidosis is a rare disorder caused by clonal expansion of CD38Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor [In relapsed or refractory AL amyloidosis, daratumumab has demonstrated an acceptable safety profile and encouraging efficacy in terms of hematologic response rates and improvement in organ function [To determine whether the efficacy and safety results of D-VCd in Asian patients with newly diagnosed AL amyloidosis are similar to those observed in the global study population, we performed a post hoc analysis of Asian patients (enrolled at sites in Japan, Korea, and China) from ANDROMEDA.